Serum Levels of Perfluoroalkyl Substances (PFAS) in Adolescents and Young Adults Exposed to Contaminated Drinking Water in the Veneto Region, Italy: A Cross-Sectional Study Based on a Health Surveillance Program.


Journal

Environmental health perspectives
ISSN: 1552-9924
Titre abrégé: Environ Health Perspect
Pays: United States
ID NLM: 0330411

Informations de publication

Date de publication:
02 2020
Historique:
entrez: 19 2 2020
pubmed: 19 2 2020
medline: 22 7 2020
Statut: ppublish

Résumé

In spring 2013, groundwater of a vast area of the Veneto Region (northeastern Italy) was found to be contaminated by perfluoroalkyl substances (PFAS) from a PFAS manufacturing plant active since the late 1960s. Residents were exposed to high concentrations of PFAS, particularly perfluorooctanoic acid (PFOA), through drinking water until autumn 2013. A publicly funded health surveillance program is under way to aid in the prevention, early diagnosis, and treatment of chronic disorders possibly associated with PFAS exposure. The objectives of this paper are: The health surveillance program offered to residents of municipalities supplied by contaminated waterworks includes a structured interview, routine blood and urine tests, and measurement of 12 PFAS in serum by high-performance liquid chromatography-tandem mass spectrometry. We studied 18,345 participants born between 1978 and 2002, 14-39 years of age at recruitment. Multivariable linear regression was used to identify sociodemographic, lifestyle, dietary, and reproductive predictors of serum PFAS concentrations. The PFAS with the highest serum concentrations were PFOA [median Serum PFOA concentrations were high relative to concentrations in populations with background residential exposures only. Interindividual variation of serum PFAS levels was partially explained by the considered predictors. https://doi.org/10.1289/EHP5337.

Sections du résumé

BACKGROUND
In spring 2013, groundwater of a vast area of the Veneto Region (northeastern Italy) was found to be contaminated by perfluoroalkyl substances (PFAS) from a PFAS manufacturing plant active since the late 1960s. Residents were exposed to high concentrations of PFAS, particularly perfluorooctanoic acid (PFOA), through drinking water until autumn 2013. A publicly funded health surveillance program is under way to aid in the prevention, early diagnosis, and treatment of chronic disorders possibly associated with PFAS exposure.
OBJECTIVES
The objectives of this paper are:
METHODS
The health surveillance program offered to residents of municipalities supplied by contaminated waterworks includes a structured interview, routine blood and urine tests, and measurement of 12 PFAS in serum by high-performance liquid chromatography-tandem mass spectrometry. We studied 18,345 participants born between 1978 and 2002, 14-39 years of age at recruitment. Multivariable linear regression was used to identify sociodemographic, lifestyle, dietary, and reproductive predictors of serum PFAS concentrations.
RESULTS
The PFAS with the highest serum concentrations were PFOA [median
CONCLUSIONS
Serum PFOA concentrations were high relative to concentrations in populations with background residential exposures only. Interindividual variation of serum PFAS levels was partially explained by the considered predictors. https://doi.org/10.1289/EHP5337.

Identifiants

pubmed: 32068468
doi: 10.1289/EHP5337
pmc: PMC7064325
doi:

Substances chimiques

Alkanesulfonic Acids 0
Caprylates 0
Drinking Water 0
Fluorocarbons 0
Sulfonic Acids 0
Water Pollutants, Chemical 0
perfluorohexanesulfonic acid 355-46-4
perfluorooctanoic acid 947VD76D3L
perfluorooctane sulfonic acid 9H2MAI21CL

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

27007

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Références

Environ Health Perspect. 2009 Dec;117(12):1873-82
pubmed: 20049206
Environ Int. 2013 Oct;60:128-36
pubmed: 24041736
Fertil Steril. 2015 Jan;103(1):184-9
pubmed: 25450302
Environ Health Perspect. 2007 Sep;115(9):1298-305
pubmed: 17805419
Environ Int. 2013 Apr;54:74-84
pubmed: 23419425
J Occup Environ Med. 2006 Aug;48(8):759-70
pubmed: 16902368
Epidemiology. 2014 Mar;25(2):255-64
pubmed: 24407430
Environ Health Perspect. 2010 Feb;118(2):197-202
pubmed: 20123614
Environ Int. 2017 Feb;99:15-28
pubmed: 27884404
Environ Health Perspect. 2014 Feb;122(2):187-92
pubmed: 24280536
Sci Total Environ. 2017 Dec 15;603-604:352-360
pubmed: 28633112
J Hypertens. 2018 Oct;36(10):1953-2041
pubmed: 30234752
Chem Biol Interact. 2002 Mar 20;139(3):301-16
pubmed: 11879818
Environ Sci Technol. 2011 Oct 1;45(19):8006-14
pubmed: 21517063
Toxicol Sci. 2008 Jul;104(1):40-53
pubmed: 18353799
Chemosphere. 2010 Aug;80(10):1125-30
pubmed: 20633921
Environ Pollut. 2017 Sep;228:50-60
pubmed: 28505513
Arch Pediatr Adolesc Med. 2010 Sep;164(9):860-9
pubmed: 20819969
Environ Res. 2005 Oct;99(2):253-61
pubmed: 16194675
Environ Health Perspect. 2007 Feb;115(2):226-30
pubmed: 17384769
Chemosphere. 2013 Nov;93(10):2419-25
pubmed: 24050716
Environ Health Perspect. 2009 Jul;117(7):1083-8
pubmed: 19654917
Environ Res. 2019 Dec;179(Pt A):108743
pubmed: 31542491
Environ Health Perspect. 2008 May;116(5):651-7
pubmed: 18470314
Chemosphere. 2015 Jun;129:126-34
pubmed: 25108894
Int J Hyg Environ Health. 2017 Oct;220(7):1195-1198
pubmed: 28821426
Environ Health Perspect. 2013 Oct;121(10):1207-13
pubmed: 23838280
Toxicology. 2009 Feb 4;256(1-2):65-74
pubmed: 19059455
Environ Sci Technol. 2013 Jul 16;47(14):7974-81
pubmed: 23777259
Occup Environ Med. 2018 Jan;75(1):46-51
pubmed: 29133598
Environ Health Perspect. 2007 Nov;115(11):1596-602
pubmed: 18007991
Environ Int. 2015 Nov;84:71-81
pubmed: 26232143
Environ Health Perspect. 2012 Jul;120(7):1036-41
pubmed: 22453676
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
PLoS One. 2016 Nov 8;11(11):e0166127
pubmed: 27824939
Environ Int. 2016 Jul-Aug;92-93:357-65
pubmed: 27132161
Environ Res. 2015 Oct;142:471-8
pubmed: 26257032
Environ Health Perspect. 2014 Dec;122(12):1299-305
pubmed: 25260175
Environ Health Perspect. 2017 Oct 02;125(10):107001
pubmed: 28974480
Toxicology. 2006 Oct 3;227(1-2):156-64
pubmed: 16978759
Environ Int. 2018 Jan;110:149-159
pubmed: 29108835
J Expo Sci Environ Epidemiol. 2019 Mar;29(2):131-147
pubmed: 30470793
Toxicol Sci. 2004 Dec;82(2):394-406
pubmed: 15470233

Auteurs

Gisella Pitter (G)

Screening and Health Impact Assessment Unit, Azienda Zero-Veneto Region, Padua, Italy.

Filippo Da Re (F)

Directorate of Prevention, Food Safety, and Veterinary Public Health-Veneto Region, Venice, Italy.

Cristina Canova (C)

Unit of Biostatistics, Epidemiology, and Public Health-University of Padua, Padua, Italy.

Giulia Barbieri (G)

Unit of Biostatistics, Epidemiology, and Public Health-University of Padua, Padua, Italy.

Maryam Zare Jeddi (M)

Unit of Biostatistics, Epidemiology, and Public Health-University of Padua, Padua, Italy.

Francesca Daprà (F)

Laboratory Department-Regional Agency for Environmental Prevention and Protection-Veneto Region, Venice, Italy.

Flavio Manea (F)

Laboratory Department-Regional Agency for Environmental Prevention and Protection-Veneto Region, Venice, Italy.

Rinaldo Zolin (R)

PFAS Team-Local Health Unit "Azienda ULSS 8 Berica", Vicenza, Italy.

Anna Maria Bettega (AM)

PFAS Team-Local Health Unit "Azienda ULSS 8 Berica", Vicenza, Italy.

Giampaolo Stopazzolo (G)

PFAS Team-Local Health Unit "Azienda ULSS 8 Berica", Vicenza, Italy.

Silvia Vittorii (S)

PFAS Team-Local Health Unit "Azienda ULSS 8 Berica", Vicenza, Italy.

Lorena Zambelli (L)

Epidemiology, Prevention of Chronic Disorders, Screening and Health Promotion Unit-Local Health Unit "Azienda ULSS 9 Scaligera", Verona, Italy.

Marco Martuzzi (M)

Regional Office for Western Pacific-World Health Organization, Seoul, Republic of Korea.

Domenico Mantoan (D)

Health and Social Area-Veneto Region, Venice, Italy.

Francesca Russo (F)

Directorate of Prevention, Food Safety, and Veterinary Public Health-Veneto Region, Venice, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH